NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma

Cancer Immunity

Volumn 13, Issue 3, 2013, Pages

  von Boehmer, Lotta ^a   Mattle, Muriel ^a   Bode, Peter ^a   Landshammer, Alexandro ^a   Schäfer, Carolin ^b   Nuber, Natko ^a,c   Ritter, Gerd ^d   Old, Lloyd ^d   Moch, Holger ^b   Schäfer, Niklaus ^a   Jäger, Elke ^e   Knuth, Alexander ^a   van den Broek, Maries ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e KRANKENHAUS NORDWEST   (Germany)

Author keywords

Cancer Testis antigen; Escape; Immunosurveillance; Melanoma; NY ESO 1

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; CANCER VACCINE; EPITOPE; IMMUNOGLOBULIN G; IPILIMUMAB; MAGE C1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; NY ESO 1 ANTIGEN; TEMOZOLOMIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINIA VACCINE; VINDESINE; CTAG1B PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADULT; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CASE REPORT; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CLINICAL FEATURE; COLON METASTASIS; DISEASE DURATION; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; INOPERABLE CANCER; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS RESECTION; METASTATIC MELANOMA; NEUROPATHY; TUMOR ESCAPE; CANCER/TESTIS ANTIGEN; ESCAPE BEHAVIOR; IMMUNOLOGY; MELANOMA; METASTASIS; MIDDLE AGED; NY-ESO-1; PATHOLOGY; SECONDARY;

CANCER/TESTIS ANTIGEN; ESCAPE; IMMUNOSURVEILLANCE; MELANOMA; NY-ESO-1;

ANTIGENS, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED;

EID: 84880171734     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing domi-nant negative IFN gamma receptors. Immunity 1994; 1: 447-456. (PMID: 7895156)
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrat-ing immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570. (PMID: 21436444)
3. Chen YT, Güre AO, Tsang S, Stockert E, Jäger E, Knuth A, Old LJ. Identification of multiple cancer/testis antigens by allogeneic anti-body screening of a melanoma cell line library. Proc Natl Acad Sci U S A 1998; 95: 6919-6923. (PMID: 9618514)
4. Scanlan MJ, Güre AO, Jungbluth AA, Old LJ, Chen YT. Cancer/tes-tis antigens: an expanding family of targets for cancer immunother-apy. Immunol Rev 2002; 188: 22-32. (PMID: 12445278)
5. Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen YT, Old LJ. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95: 1-30. (PMID: 16860654)
6. Jäger E, Gnjatic S, Nagata Y, Stockert E, Jäger D, Karbach J, Neu-mann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000; 97: 12198-12203. (PMID: 11027314)
7. Jäger E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jäger D, Panicali D, Hoffman E, Pan L, Oettgen H, Old LJ, Knuth A. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-spe-cific immune responses in cancer patients. Proc Natl Acad Sci U S A 2006; 103: 14453-14458. (PMID: 16984998)
8. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maras-kovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 2004; 101: 10697-10702. (PMID: 15252201)
9. Bender A, Karbach J, Neumann A, Jäger D, Al-Batran SE, Atmaca A, Weidmann E, Biskamp M, Gnjatic S, Pan L, Hoffman E, Old LJ, Knuth A, Jäger E. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun 2007; 7: 16. (PMID: 17944437)
10. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007; 104: 12837-12842. (PMID: 17652518)
11. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 2008; 31: 849-857. (PMID: 18833002)
12. Karbach J, Neumann A, Atmaca A, Wahle C, Brand K, von Boehmer L, Knuth A, Bender A, Ritter G, Old LJ, Jäger E. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin Cancer Res 2011; 17: 861-870. (PMID: 21163871)
13. Garrido F, Ruiz-Cabello F. MHC expression on human tumors--its relevance for local tumor growth and metastasis. Semin Cancer Biol 1991; 1: 3-10. (PMID: 1912516)
14. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111. (PMID: 11323675)
15. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95: 7556-7561. (PMID: 9636188)
16. van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996; 184: 1781-1790. (PMID: 8920866)
17. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lym-phoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002; 196: 129-134. (PMID: 12093877)
18. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Shreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-907. (PMID: 18026089)
19. Jäger E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expres-sion in melanoma tissues and CD8+ cytotoxic-T cell responses: evi-dence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996; 66: 470-476. (PMID: 8635862)
20. Jäger E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jäger D, Arand M, Ritter G, Old LJ, Knuth A. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correla-tion with clinical events. Int J Cancer 1999; 84: 506-510. (PMID: 10502728)
21. Jäger E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jäger D, Oesch F, Knuth A. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expres-sion in metastatic melanoma. Int J Cancer 1997; 71: 142-147. (PMID: 9139833)
22. Jäger E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jäger D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old LJ, Knuth A. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A 2000; 97: 4760-4765. (PMID: 10781081)
23. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lago-rce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindo-houé F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964. (PMID: 17008531)
24. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Brune-val P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666. (PMID: 16371631)
25. Halama N, Michel S, Kloor M, Zoernig I, Pommerencke T, von Knebel Doeberitz M, Schirmacher P, Weitz J, Grabe N, Jäger D. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun 2009; 9: 1. (PMID: 19226101)
26. Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosup-pressive drugs. Br Med J 1979; 2: 1461-1466. (PMID: 393355)
27. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Sny-der JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, Copeland G, Finch JL, Fleissner ML, Goodman MT, Kahn A, Koch L, Lynch CF, Madeleine MM, Pawlish K, Rao C, Williams MA, Castenson D, Curry M, Parsons R, Fant G, Lin M. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306: 1891-1901. (PMID: 22045767)
28. Gnjatic S, Old LJ, Chen YT. Autoantibodies against cancer antigens. Methods Mol Biol 2009; 520: 11-19. (PMID: 19381944)
29. Theurillat JP, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B, Chen YT, Jäger D, Knuth A, Moch H. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T cell and CD79a+ plasmacytic/B-cell infiltration. Int J Cancer 2007; 120: 2411-2417. (PMID: 17294444)
30. von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Her-manns T, Sulser T, Jungbluth AA, Old LJ, Kristiansen G, van den Broek M, Moch H, Knuth A, Wild PJ. MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. PLoS One 2011; 6: e21366. (PMID: 21754986)